Clinical Trials Directory

Trials / Terminated

TerminatedNCT00003654

Diagnostic Study to Identify Sentinel Lymph Nodes in Women With Stage I or Stage II Breast Cancer

Diagnostic Study of Patent Blue V Dye to Identify Sentinel Lymph Nodes in Patients With Stage I or IIA Breast Cancer

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
200 (estimated)
Sponsor
UNICANCER · Academic / Other
Sex
Female
Age
0 Years – 120 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Diagnostic procedures, such as blue dye or imaging to identify sentinel lymph nodes, may improve the ability to detect the extent of disease and help plan effective surgery for removing breast tumors. PURPOSE: Diagnostic trial to study the effectiveness of blue dye and an imaging procedure to identify the sentinel lymph node under the arm in women with stage I or stage II breast cancer.

Detailed description

OBJECTIVES: I. Determine whether the concept of a sentinel lymph node within the axillary nodal basin is valid in staging breast cancer. II. Determine the sensitivity of combined methods of identification of sentinel lymph nodes by patent blue V dye and gamma probe detection in these women. OUTLINE: Patients receive patent blue V dye injection peritumorally prior to surgery. Preoperative lymphoscintigraphy is performed using technetium Tc 99 sulfur rhenium colloid injected around the tumor associated with intraoperative gamma probe detection. Nonpalpable tumors receive a localized injection using stereotactic injection techniques. Patients then undergo standard axillary (level I and II) lymph node dissection. PROJECTED ACCRUAL: A total of 200 patients will be accrued for this study within 1 year.

Conditions

Interventions

TypeNameDescription
DRUGpatent blue V dye
PROCEDURElymphangiography
PROCEDUREradionuclide imaging
PROCEDUREsentinel lymph node biopsy
RADIATIONtechnetium Tc 99m sulfur colloid

Timeline

Start date
1997-09-01
Primary completion
2000-01-01
Completion
2000-01-01
First posted
2004-08-26
Last updated
2021-02-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT00003654. Inclusion in this directory is not an endorsement.